[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1341795A2 - Derives de resiniferatoxine nouvellement marques - Google Patents

Derives de resiniferatoxine nouvellement marques

Info

Publication number
EP1341795A2
EP1341795A2 EP01986690A EP01986690A EP1341795A2 EP 1341795 A2 EP1341795 A2 EP 1341795A2 EP 01986690 A EP01986690 A EP 01986690A EP 01986690 A EP01986690 A EP 01986690A EP 1341795 A2 EP1341795 A2 EP 1341795A2
Authority
EP
European Patent Office
Prior art keywords
formula
compound
iodine
group
substituent selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01986690A
Other languages
German (de)
English (en)
Inventor
Mark E. Mcdonnell
Larry E. Weaner
Sui-Po Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of EP1341795A2 publication Critical patent/EP1341795A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to a method for preparing iodinated or labeled vanilloid receptor ligands. More particularly, this invention relates to a method for preparing an iodinated or labeled resiniferatoxin derivative and congeners thereof and a method for use in a vanilloid receptor binding assay.
  • Noxious chemical, thermal and mechanical stimuli excite peripheral nerve endings of small diameter sensory neurons (nociceptors) in sensory ganglia (e. g., dorsal root, nodose and trigeminal ganglia) and initiate signals that are perceived as pain.
  • sensory ganglia e. g., dorsal root, nodose and trigeminal ganglia
  • These neurons are crucial for the detection of harmful or potentially harmful stimuli (heat) and tissue damage (H + (local tissue acidosis), and/or stretch) which arise from changes in the extracellular space during inflammatory or ischaemic conditions (Wall, P. D., and Melzack, R., Textbook of Pain. 1994, New York: Churchill Livingstone).
  • Capsaicin (N-[(4-hydroxy-3-methoxyphenyl)methyI]-8-methyl-6- nonenamide), the main pungent ingredient in "hot” capsicum peppers, interacts with specific membrane recognition sites called vanilloid receptors (VR). These proteins are expressed almost exclusively by primary sensory neurons involved in nociception and neurogenic inflammation (Bevan, S., and Szolcsanyi, J., Sensory neuron-specific actions of capsaicin: mechanisms and applications, Trends Pharmacol. Sci., 1990, 11 , 330-3).
  • Capsaicin itself is a selective activator of thinly myelinated or unmyelinated nociceptive afferents (Szolcsanyi, J., Actions of capsaicin on sensory receptors, In Capsaicin Study, Pain, J. N. Wood, ed.: Academic, London, UK, 1993, pp. 1-26; and Szolcsanyi, J., Capsaicin-sensitive sensory nerve terminals with local and systemic efferent functions: facts and scopes of an unorthodox neuroregulatory mechanism, Prog. Brain Res., 1996, 113, 343-359). Capsaicin and structurally-related derivatives show structure-function relationships and these effects can be blocked by a selective antagonist, capsazepine.
  • RTX tricyclic diterpene resin iferatoxin
  • Capsaicin excites the neuron resulting in calcium influx, the release of various neuropeptides such as CGRP and SP (Purkiss, J., Welch, M., Doward, S. and Foster, K, Capsaicin-stimulated release of substance P from culture dorsal root ganglion neurons: involvement of two distinct mechanisms, Biochem.
  • cytokine release (Veronesi, B., Oortgiesen, M., Carter, J. D. and Devlin, R.B., Particulate matter initiates inflammatory cytokine release by activation of capsaicin and acid receptors in a human bronchial epithelial cell line, Toxicol. Appl. Pharmacol., 1999, 154, 106-115). These events are believed to contribute to pain states and inflammation. Additionally, capsaicin and RTX can cause vanilloid receptor desensitization (Acs, G., Biro, T., Ace, P., Modarres, S. and Blumberg, P.
  • VR1 is a ligand-gated non-selective cation channel that shows pronounced outward rectification (Caterina et al., 1997).
  • the vanilloid ("capsaicin") receptor VR1 is activated by capsaicin and RTX, and activation of VR1 is blocked by the antagonists capsazepine (CPZ) (Bevan, S., Hothi, S., Hughes, G., James, I. F., Rang, H. P., Shah, K., Walpole, C. S. J., and Yeats, J.
  • Capsazepine a competitive antagonist of the sensory neuron excitant capsaicin, Br. J. Pharmacol., 1992, 107, 544-52) and ruthenium red (RR) (Wood, J. N., Winter, J., James, I. F., Rang, H. P., Yeats, J., and Bevan, S., Capsaicin-induced ion fluxes in dorsal root ganglion cells in culture, J. Neurosci., 1988, 8, 3208-20).
  • VR1 Receptors are sensitive to vanilloids, heat and protons and thus these proteins are believed to be widely involved in the initiation, modulation and modification of pain (Woolf, C. J. and Salter, M.
  • VR1 is expressed in small nociceptive neurons of the dorsal root ganglion, consistent with its role in modulating peripheral pain (Tominaga, et al., 1998; and, Michael, G. J. and Priestley, J. V., Differential expression of the mRNA for the vanilloid receptor subtype 1 in calls of the adult rat dorsal root and nodose ganglia and its downreglulation by axotomy, J. Neurosci., 1999, 19, 1844-1854).
  • Patent application WO 99/09140 identifies the vanilloid receptor (VR) as a ligand-gated, non-selective cation channel that is expressed in sensory neurons and which is involved in nociceptive processes such as hyperalgesia.
  • VR vanilloid receptor
  • Resiniferatoxin a naturally-occurring terpenoid phorbol derivative, binds to the VR protein with sub-nanomolar affinity and behaves as a functional agonist (stimulates calcium influx).
  • iodinated and labeled RTX derivatives may similarly be potent in binding to the vanilloid receptor and may therefore be useful in identifying compounds that have affinity for vanilloid receptor when utilized in a receptor-binding assay.
  • tritiated-RTX is known to display a nanomolar affinity for VR, and can be used to identify or indicate compounds that also bind to this receptor.
  • n 0 to 10, preferably 2, and R' is a fluorescent label.
  • R' is a fluorescent label.
  • biologically active congeners of RTX can be radiolabeled using the same synthetic route as for tritiated RTX, wherein such congeners have the general structure:
  • R is:
  • R., R 2 , R 4 or R 5 is labeled, for instance, with 3 H, 125 l or 131 l.
  • one of more of R.,, R 2 , R 4 , and R 5 is 3 H.
  • R 3 should be OH so that the derivative is active.
  • R 2 is hydroxy or methoxy
  • R 3 is loweralkylaryl or an aryl group having 1 to 3 rings
  • R 4 to R 7 which may be the same or different, are independently selected from the group consisting of hydrogen, hydroxy, methoxy, sulfhydryl, nitro, amino, ethoxy, halo and OCOCH 3 .
  • the present invention provides a method for preparing a resiniferatoxin derivative compound of Formula (I):
  • R 1 is a substituent selected from the group consisting of hydrogen, C ⁇ alkylcarbonyl and formyl;
  • R 2 is iodine
  • R 3 is a substituent selected from the group consisting of C 1 alkoxy and hydroxy; comprising,
  • a preferred embodiment of the method of the present invention includes a resiniferatoxin derivative compound wherein R 1 is acetyl; and, R 3 is methoxy.
  • a more preferred embodiment includes a resiniferatoxin derivative compound wherein R 2 is 127 iodine.
  • the most preferred embodiment includes a labeled resiniferatoxin derivative compound wherein R 2 is selected from the group consisting of 125 iodine and 131 iodine.
  • Another embodiment of the invention is a method for preparing a labeled resiniferatoxin derivative compound of Formula (V):
  • R 1 is a substituent selected from the group consisting of hydrogen, C ⁇ alkylcarbonyl and formyl;
  • R 3 is C 1 alkoxy; comprising,
  • C 1 _ 5 alkyl is selected from the group consisting of /-propyl, /-butyl and --butyl. In a more preferred embodiment, C,_ 5 alkyl is f-butyl.
  • the present invention also provides a resiniferatoxin derivative compound of Formula (I) for use in a vanilloid receptor binding assay:
  • R 1 is a substituent selected from the group consisting of hydrogen, C 1 . 4 alkylcarbonyl and formyl;
  • R is iodine; and, R 3 is a substituent selected from the group consisting of C 1 alkoxy and hydroxy.
  • Figure 1 shows the inhibition of [ 3 H] RTX binding to hVR1 receptors in counts per minute (cpm) as a function of the IC 50 drug concentration value in Log Mole (M) of an iodinated RTX derivative.
  • the current reference standard for identifying compounds that bind to the resiniferatoxin receptor is labeling such RTX compounds with tritium [ 3 H].
  • the use of a [ 3 H] labeled RTX compound is limited, however, by such compounds having different affinities for different tissues and high non-specific binding.
  • current methods for preparing an iodinated or labeled resiniferonal-vanilloid derivative RTX compound have been limited by undirected iodination on the aromatic ring of the vanilloid substrate, thus resulting in iodination or labeling on different and multiple positions.
  • iodine is intended to include both the nonradioactive and radioactive isotopes of iodine.
  • Preferred iodine isotopes are those commonly used in chemical reactions. Such commonly used isotopes include the nonradioactive isotope 127 iodine [ 127 l] and radioactive isotopes 125 iodine and 131 iodine.
  • iodinated RTX analogs or labeled RTX analogs have the advantage of an improved binding affinity over a [ 3 H] labeled RTX derivative, thus enabling smaller amounts of receptor sites to be detected while using a lower ligand concentration to assay those receptors.
  • the iodination reaction and consequent iodination or labeling of a RTX derivative may be consistently directed to a single position on the vanilloid substrate, thus providing a RTX compound containing a single site of iodination which is free of the limitations inherent in current methods of preparation.
  • the method of the present invention comprises iodinating the single vanilloid substrate site wherein a single iodine atom may be consistently incorporated. Accordingly, the present method may be used to iodinate the ortho position on the phenyl ring of a para-O-carbonylalkyl substituted homovanillic acid substrate of an RTX derivative compound.
  • a preferred embodiment of the present method for iodinating or labeling a RTX derivative compound comprises iodinating or labeling the ortho position on the phenyl ring of a homovanillic acid acetate ester derivative substrate with a single iodine atom or iodine-based label, preferably 125 l; and, coupling the iodinated or labeled vanilloid derivative with a resiniferonal orthophenylacetate alcohol to form a resiniferatoxin or labeled resiniferatoxin derivative compound of the present invention.
  • the advantage of the method of the present invention is embodied in a "directed-iodination" in which a single iodine substituent is specifically introduced onto a single specific carbon center of a homovanillic acid substrate or intermediate compound.
  • the iodination is directed to the ortho position of the phenyl group in the vanilloid acid substrate by an O-acetate protecting group.
  • O-acetate protecting group We have also discovered that iodination at the ortho position is not accessible using other common protecting groups, particularly those that do not withdraw electron density from the aromatic system of the homovanillic acid.
  • R 1 group of the homovanillic acid substrate other than C 1.4 alkylcarbonyl and formyl preferably, R 1 is selected from acetyl and formyl; and, more preferably, R 1 is acetyl
  • R 1 is selected from acetyl and formyl; and, more preferably, R 1 is acetyl
  • the efficiency of the instant method compared to the lack of specificity resulting from the use of previously disclosed iodination reactions for the homovanillic acid substrate can be characterized using techniques known to those skilled in the art such as, but not limited to, HPLC.
  • [ 3 H] labeled RTX analogs have binding affinities for the vanilloid receptor at generally three to four orders of magnitude less than the iodinated or labeled RTX derivatives of the present invention.
  • modifications of the aryl ring affect binding (C. S. Walpole, S. Bevan, G. Bloomfield, R. Breckenridge, I. F. James, T. Ritchie, A. Szallasi, J. Winter, R. Wrigglesworth., Similarities and Differences in the Structure-Activity Relationships of Capsaicin and Resiniferatoxin
  • the scope of the present invention includes a method for iodinating a homovanillic acid intermediate, a method for labeling a homovanillic acid intermediate and a method for using such intermediates in a RTX binding assay.
  • a compound or an intermediate iodinated or labeled by the method of this invention may be used to subsequently prepare other novel RTX compounds that carry the unique and novel site of iodination.
  • compounds in which R 1 is hydrogen may not be suitable for production by the methods described above.
  • a particular step for which R 1 is hydrogen may not be suitable is that step wherein an iodinated or labeled homovanillic acid intermediate compound is produced.
  • R is C 1 alkylcarbonyl or formyl.
  • Compounds in which R 1 is hydrogen that may be produced are those from analogous compounds in which R 1 is C 1 alkylcarbonyl or formyl by either of two methods.
  • the R 1 group may be cleaved chemically in a separate chemical reaction using common literature methods or specifically, as disclosed herein, with pyrrolidine.
  • the in situ esterase or pH conditions may cleave the R 1 group to hydrogen.
  • R 1 is a substituent selected from the group consisting of hydrogen, formyl, acetyl, ethylcarbonyl and propylcarbonyl; more preferably, R 1 is a substituent selected from the group consisting of hydrogen, formyl and acetyl; most preferably, R 1 is a substituent selected from the group consisting of hydrogen and acetyl;
  • R 2 is a substituent selected from the group consisting of 125 iodine, 127 iodine and 131 iodine; more preferably, R 2 is a substituent selected from the group consisting of 125 iodine and 127 iodine;
  • R 3 is a substituent selected from C alkoxy; more preferably, R 3 is a substituent selected from methoxy, ethoxy, propoxy and butoxy; and, most preferably, R 3 is methoxy.
  • Exemplified compounds of the present invention are those of the formula:
  • R 1 and R 2 are selected from
  • Scheme A illustrates a method for producing an iodinated vanilloid substrate of a resiniferatoxin derivative by the use of an electron withdrawing group, whereby the homovanillic acid hydroxyl group is derivatized and the acetate ester group necessary to direct the site of iodination is formed.
  • Compound A1 used as the starting material was derived from homovanillic acid by derivatizing the hydroxyl moiety and forming the acetate ester group using excess acetic anhydride and a catalytic amount of sulfuric acid. Compound A1 was then treated with an in situ generated electrophilic iodine species for 24 hours at room temperature which resulted in Compound A2. The iodinated homovanillic acid Compound A2 was then coupled with a resiniferonol orthophenylacetate alcohol Compound A3 by a dimethylaminopyridine mediated catalysis and carbodiimide mediated esterification under suitable conditions after two hours to form the target Compound A4.
  • Scheme B illustrates a method for producing an iodinated vanilloid substrate of a resiniferatoxin derivative wherein R 1 is hydrogen by cleaving the acetyl R substituent from Compound A4 with an amine base such as pyrrolidine to produce Compound B1. This reaction was carried out at room temperature for two hours in methylene chloride.
  • Scheme C illustrates a method for producing a labeled vanilloid substrate of a resiniferatoxin derivative by the direct labeling of homovanillic acid Compound A1 using hot sodium iodide in the presence of an oxidant to form Compound C1. This reaction is carried out in methylene chloride at room temperature for several hours.
  • Scheme D illustrates a method for producing a labeled vanilloid substrate of a resiniferatoxin derivative by the stannylation of an iodinated compound of the present invention to a trimethyl tin compound and subsequent conversion of the trimethyl tin to a 125 l or 131 l labeled compound, incorporating methods well described in the literature and providing an alternative preparation route.
  • Iodinated RTX derivatives of the present invention were tested for their ability to inhibit the binding of [ 3 H] RTX to hVR1 receptors in a [ 3 H] RTX Binding Assay.
  • HEK293 cells were transfected with human VR1 vanilloid receptors, as described in United States Patent Application 09/292700 to Dubin, A., et. al, filed on April 15, 1999 (herein incorporated by reference), and washed with Hank's Balanced Salt Solution, dissociated with cell dissociation buffer (Sigma), and then centrifuged at 1000 x g for 5 min.
  • Cell pellets were homogenized in cold 20 mM HEPES buffer, pH 7.4, containing 5.8 mM NaCI, 320 mM sucrose, 2 mM MgCI 2 , 0.75 CaCI 2 and 5 mM KCI and centrifuged at 1000 x g for 15 min. The resultant supemate was then centrifuged at 40,000 x g for 15 min.
  • the pelleted membranes were kept in an -80°C freezer.
  • reaction mixture was then cooled to 4°C, added 0.1 mg ⁇ ,-acid glycoprotein to each sample and incubated at 4°C for 15 min.
  • the samples were centrifuged at 18500 x g for 15 min.
  • the tip of the microcentrifuge tube containing the pellet was cut off. Bound radioactivity was quantified by scintillation counting. Non-specific binding was tested in the presence of 200 nM unlabeled RTX.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne des dérivés de résinifératoxine servant dans un test de liaison de récepteur vanilloïde et des procédés de production de ceux-ci.
EP01986690A 2000-10-10 2001-10-09 Derives de resiniferatoxine nouvellement marques Withdrawn EP1341795A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23962700P 2000-10-10 2000-10-10
US239627P 2000-10-10
PCT/US2001/042548 WO2002030937A2 (fr) 2000-10-10 2001-10-09 Derives de resiniferatoxine nouvellement marques

Publications (1)

Publication Number Publication Date
EP1341795A2 true EP1341795A2 (fr) 2003-09-10

Family

ID=22902995

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01986690A Withdrawn EP1341795A2 (fr) 2000-10-10 2001-10-09 Derives de resiniferatoxine nouvellement marques

Country Status (5)

Country Link
US (1) US7112685B2 (fr)
EP (1) EP1341795A2 (fr)
JP (1) JP2004511488A (fr)
AU (1) AU2002219783A1 (fr)
WO (1) WO2002030937A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359316B1 (en) * 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US11634384B2 (en) 2014-11-25 2023-04-25 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CA3025268A1 (fr) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Promedicaments a base d'agonistes de trpv1 phenoliques en association avec des anesthesiques locaux et des vasoconstricteurs pour ameliorer une anesthesie locale

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
AU5460598A (en) 1996-11-15 1998-06-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists
CA2298540A1 (fr) 1997-08-20 1999-02-25 David J. Julius Sequences nucleotidiques codant pour le recepteur de la capsicine, polypeptides lies au recepteur de la capsicine et leur utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0230937A2 *

Also Published As

Publication number Publication date
JP2004511488A (ja) 2004-04-15
AU2002219783A1 (en) 2002-04-22
WO2002030937A2 (fr) 2002-04-18
US7112685B2 (en) 2006-09-26
US20040230064A1 (en) 2004-11-18
WO2002030937A3 (fr) 2003-02-06

Similar Documents

Publication Publication Date Title
Polossek et al. 6-Alkyl-12-formylindolo [2, 1-a] isoquinolines. Syntheses, estrogen receptor binding affinities, and stereospecific cytostatic activity
EP4038058A1 (fr) Dérivés de cannabinoïdes
CN112645809B (zh) 一种基于甲萘醌结构的新型冠状病毒3cl蛋白酶抑制剂
Murakami et al. Aggregate morphology and intermembrane interaction of synthetic peptide lipids bearing various head groups
McDonnell et al. Synthesis and in vitro evaluation of a novel iodinated resiniferatoxin derivative that is an agonist at the human vanilloid VR1 receptor
Lu et al. A fluorimetric liquid chromatography for highly sensitive analysis of very long chain fatty acids as naphthoxyethyl derivatives
US7112685B2 (en) Labeled resiniferatoxin derivatives
Moreno-Yruela et al. Synthesis of trifluoromethyl ketone containing amino acid building blocks for the preparation of peptide-based histone deacetylase (HDAC) inhibitors
CN114621310A (zh) 基于雷公藤红素的靶向Prdx2降解剂及其制备方法与医药用途
WO2022017317A1 (fr) Procédé de synthèse à grande échelle de tétrodotoxine
Schneider et al. 2-Phenylindenes. Development of a new mammary tumor-inhibiting antiestrogen by combination of estrogenic side effect-lowering structural elements
CN115010658B (zh) 一种化合物及其制备方法与应用
Foley et al. Preparation of FRET reporters to support chemical probe development
JPH06329678A (ja) 多環式化合物及びその製造方法
CN111892537B (zh) 阿朴菲类生物碱衍生物及其制备方法与用途
Etievant et al. Requirements for P-glycoprotein recognition based on structure-activity relationships in the podophyllotoxin series
EP0656422A1 (fr) Essai de CAT
Goto et al. New sensitive fluorescence labeling reagent for high performance liquid chromatography of hydroxysteroids
Santa et al. A new fluorogenic reagent for carboxylic acids, 7-acetylamino-4-mercapto-2, 1, 3-benzoxadiazole (AABD-SH), derived from an empirical method for predicting fluorescence characteristics
Sharma et al. Synthesis and binding to tubulin of colchicine spin probes
Hoque et al. Design and synthesis of mono and bicyclic tetrapeptides thioester as potent inhibitor of histone deacetylases
CN1318408C (zh) 一种含氮杂环β－榄香烯酰胺类衍生物其制备及应用
CN114685457B (zh) 一种恩扎鲁胺光亲和探针及其制备方法
Miranda et al. Transesterification of peptide esters and peptidyl resins in methanol‐containing calcium acetate
CN114634488B (zh) 琥珀酰亚胺酯及其制备、处理和检测方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030509

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20031201

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051220